Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.55 |
| ▸ | CES1 | P23141 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA7 | P43166 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31237092 | 0.87 | TSHR (0.50) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL2001481 | 0.85 | TSHR (0.52) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL8782448 | 0.84 | TSHR (0.49) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL2184188 | 0.82 | TSHR (0.48) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL4510914 | 0.81 | TSHR (0.47) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL4726807 | 0.81 | TSHR (0.47) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL15048802 | 0.81 | TSHR (0.47) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL7813719 | 0.81 | TSHR (0.52) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL31237050 | 0.80 | CYP4F2 (0.56) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL13745873 | 0.80 | CES2 (0.49) | CES2CES1TSHRKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-14 | — | — | US | disclosed |
| US-20250171457-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-05-29 | — | — | US | disclosed |
| US-20250084093-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-03-13 | — | — | US | disclosed |
| EP-4446312-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-10-16 | — | — | EP | disclosed |
| CN-118488944-A | Nitrogen-containing heterocyclic compound having Nrf2 activation | 中外制药株式会社 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023132369-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | 中外製薬株式会社 | 2023-07-13 | — | — | WO | disclosed |
| CN-217068856-U | Pazufloxacin synthesizer | 赤峰万泽药业股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| EP-2338935-B1 | FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF | ASAHI GLASS CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-20110172336-A1 | FLUOROCOPOLYMER COMPOSITION AND ITS PRODUCTION PROCESS | ASAHI GLASS COMPANY, LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2338935-A1 | FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF | ASAHI GLASS COMPANY, LIMITED (JP) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | KEAP1, NFE2L2, BACH1 | CES2 2878/4885CES1 1817/4885TSHR 2108/4885 |
| US-20250171457-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | KEAP1, NFE2L2, BACH1 | CES2 2878/4885CES1 1817/4885TSHR 2108/4885 |
| US-20250084093-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | KEAP1, NFE2L2, BACH1 | CES2 2899/4885CES1 1779/4885TSHR 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.